CD Protein Inhibitors 

  Products    Products    Diseases    News 


«12...7677787980818283848586...39323933»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    A RARE ADVERSE REACTION: PEMBROLIZUMAB-INDUCED ANGIOEDEMA (Convention Center Exhibit Hall: Poster Area 1) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_1081;    
    Angioedema is a rare but potentially life-threatening adverse reaction that may occur in patients undergoing Pembrolizumab therapy. Though this is a rare case of the adverse event, further research is needed to elucidate the underlying mechanisms to optimize strategies for its prevention and management.
  • ||||||||||  Nucala (mepolizumab) / GSK, Fasenra (benralizumab) / AstraZeneca, Rituxan (rituximab) / Roche
    AORTIC INSUFFICIENCY: A GRAVE PRESENTATION OF EGPA (Convention Center Exhibit Hall: Rapid Fire Area 2B) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_1073;    
    The learning point from the case is that EGPA should be considered early on in patients with refractory asthma. If recognized early, it prevents significant morbidity and mortality.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca
    DURVALUMAB ASSOCIATED ACUTE EOSINOPHILIC PNEUMONIA: A CASE REPORT (Convention Center Exhibit Hall: Rapid Fire Area 2B) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_1071;    
    Our case highlights the importance of keeping PD-L1 inhibitors, especially durvalumab as a possible cause of AEP, and to strongly consider alternative therapy if diagnosis is suspected. Prompt therapy with steroids leads to improvement in symptoms and radiographic abnormalities.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    A CASE OF PEMBROLIZUMAB-INDUCED ACUTE EOSINOPHILIC PNEUMONIA (Convention Center Exhibit Hall: Rapid Fire Area 2B) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_1069;    
    AEP can carry significant morbidity if not recognized and treated promptly. Therefore, it is important to recognize the association between AEP and many of our commonly used medications.
  • ||||||||||  THROMBOEMBOLIC RISK AMONG IMMUNE CHECKPOINT INHIBITOR RECIPIENTS WITH METASTATIC LUNG CANCER (Convention Center 258 B) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_1024;    
    PD-1 recipients (cemiplimab, nivolumab, and pembrolizumab) were at significantly higher risk of PE than PD-L1 recipients (atezolizumab and durvalumab). CLINICAL IMPLICATIONS: Clinicians caring for patients with metastatic lung cancer treated with ICIs should be wary of signs and symptoms of thromboembolism, as these patients are at an even higher risk of TEE than the baseline risk excess of metastatic cancer.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Zydelig (idelalisib) / Gilead
    Journal:  PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4/6 inhibitor palbociclib via PLK1 in B-cell lymphoma. (Pubmed Central) -  Jul 31, 2024   
    Furthermore, we also validated the pharmacological efficacy of CDK4/6 inhibitor palbociclib and its synergy effect with PI3K inhibitor idelalisib utilizing in vitro cell lines and in vivo cell-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models. Our results provided sufficient pre-clinical evidence to support the potential combination of palbociclib and idelalisib for DLBCL and MCL patients.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal, Cytokine release syndrome:  Cytokine Release Syndrome More than Two Years after Pembrolizumab Introduction: A Case Report. (Pubmed Central) -  Jul 31, 2024   
    Considering the possible diagnosis of immune-related cytokine release syndrome (CRS), the patient was administered prednisolone (1 mg/kg/day) and showed improvement. In conclusion, CRS can occur even long after the initial administration of immune checkpoint inhibitor therapy.
  • ||||||||||  Rituxan (rituximab) / Roche
    Clinical, Retrospective data, Review, Journal:  Immunosuppression for adult steroid-dependent or frequently relapsing nephrotic syndrome: A systematic review and meta-analysis. (Pubmed Central) -  Jul 31, 2024   
    Patients with no long-term benefit to PD-1 blockade were most accurately identified by PD-1T TILs. Among the commonly used immunosuppressive agents, only rituximab has a statistically significant effect in achieving complete remission among patients with SDNS/FRNS and has a relatively good safety profile, but this is limited by low quality of evidence with high degree of heterogeneity causing a lack of statistical power.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    Journal, Adverse events:  A disproportionality analysis of CDK4/6 inhibitors in the FDA adverse event reporting system (FAERS). (Pubmed Central) -  Jul 31, 2024   
    The number of AE reports for CDK4/6 inhibitors was respectively 132,494 for palbociclib 56,151 for ribociclib, and 7,014 for abemaciclib. The corresponding numbers of AE signals were 319, 517, and 59, with the number of involved System Organ Class (SOC) being 23, 23, and 15, mainly involving blood and lymphatic system disorders, respiratory, thoracic and mediastinal disorders, hepatobiliary disorders, skin and subcutaneous tissue disorders, etc. CDK4/6 inhibitors could lead to pulmonary toxicity, myelosuppression, skin reactions, etc. Special attention should be paid to abemaciclib for interstitial lung disease (ILD), erythema multiforme, and thrombosis risk; ribociclib for cardiac toxicity, hepatotoxicity, and musculoskeletal toxicity; palbociclib for neurocognitive impairment and osteonecrosis of the jaw.
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  Orbital MALT lymphoma with amyloid deposition. (Pubmed Central) -  Jul 31, 2024   
    The patient underwent local irradiation and subsequent surgical resection of the residual mass. Persistent lymphoma was found and treated with rituximab.
  • ||||||||||  Promacta (eltrombopag) / Novartis, Rituxan (rituximab) / Roche
    Biomarker, Observational data, Retrospective data, Journal:  Retrospective Evaluation of Survival and Prognostic Factors in Immune Thrombocytopenia: A Single-Center and Cross-Sectional Study. (Pubmed Central) -  Jul 31, 2024   
    It is noted that eltrombopag and rituximab, in particular, yield higher complete remission rates than immunosuppressive drugs. Considering the side effects of immunosuppressive medications, IVIg, splenectomy, and steroid therapy, the use of new agents such as eltrombopag, which are easily tolerated and have a lower risk of side effects, is expected to increase.
  • ||||||||||  Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma
    Review, Journal:  Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma. (Pubmed Central) -  Jul 31, 2024   
    Several studies have proven its efficacy in the treatment of refractory cases of DLBCL with a good safety profile, with the main adverse effects being neutropenia, thrombopenia, and liver enzyme involvement. In this review, we explain the mechanism of action of this molecule, the clinical data that have led to its acceptance by the FDA, and the new therapeutic options that are proposed in association with this drug.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Review, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker:  Immunotherapy in Breast Cancer. (Pubmed Central) -  Jul 31, 2024   
    Though belatedly, immunotherapy has entered the treatment armamentarium of breast cancer, with the approval of pembrolizumab in combination with chemotherapy in triple-negative breast cancer (TNBC) in the neoadjuvant and advanced settings, thereby paving the path for further research and integration of immune checkpoint inhibitors in other subtypes of breast cancer...Biomarkers and precise patient selection for the utilization of immunotherapy remain cardinal and are currently under investigation, with some biomarkers showing promise, such as Program Death Lignat-1 (PDL-1) Combined Positive Score, Tumor Mutation Burden (TMB), and Tumor Infiltrating Lymphocytes (TILs). This review will present the current landscape of immunotherapy, particularly checkpoint inhibitors, in different types of breast cancer.
  • ||||||||||  Bavencio (avelumab) / EMD Serono, Keytruda (pembrolizumab) / Merck (MSD), Padcev (enfortumab vedotin-ejfv) / Astellas, Pfizer
    Clinical data, Journal, Metastases:  Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy. (Pubmed Central) -  Jul 31, 2024   
    A low NLR may be an indicator of higher immunocompetence for anti-tumor immunity, suggesting that NLR may be a convenient predictive biomarker in daily practice. EV monotherapy after avelumab maintenance therapy provides favorable survival outcomes in patients with advanced UC.
  • ||||||||||  UCART CS1 / Cellectis
    Preclinical, Journal, CAR T-Cell Therapy, IO biomarker:  Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma. (Pubmed Central) -  Jul 31, 2024   
    EV monotherapy after avelumab maintenance therapy provides favorable survival outcomes in patients with advanced UC. These results demonstrate that UCARTCS1 has potent anti-MM activity against MM cell lines and primary MM cells, as well as in an MM xenograft model and support the evaluation of UCARTCS1 in patients with advanced MM.